Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 3/20 | 0.34 |
| ▸ | HSD17B14 | Q9BPX1 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.32 |
| ▸ | GPR6 | P46095 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30752139 | 0.82 | KDM4E (0.39) | KDM4EL3MBTL1ALDH1A1ALOX15IRAK4 | |
| SCHEMBL17785204 | 0.82 | KDM4E (0.56) | KDM4EL3MBTL1ALDH1A1ALOX15RAB9A | |
| SCHEMBL21241047 | 0.82 | KDM4E (0.39) | KDM4EL3MBTL1ALDH1A1ALOX15IRAK4 | |
| SCHEMBL29502454 | 0.80 | TGFBR1 (0.42) | KDM4EL3MBTL1ALDH1A1TGFBR1DPP4 | |
| SCHEMBL2827339 | 0.80 | TGFBR1 (0.42) | KDM4EL3MBTL1ALDH1A1TGFBR1DPP4 | |
| SCHEMBL12707195 | 0.79 | NOS3 (0.41) | KDM4EL3MBTL1ALDH1A1GRM5NPC1 | |
| Hydrochloric Acid SCHEMBL1022194 | 0.78 | NOS3 (0.40) | KDM4EL3MBTL1ALDH1A1GRM5NPC1 | |
| SCHEMBL31224086 | 0.77 | GAA (0.43) | KDM4EALDH1A1IRAK4GRM5NPC1 | |
| SCHEMBL29826096 | 0.77 | MAPT (0.45) | KDM4EL3MBTL1ALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL14982165 | 0.77 | MAPT (0.45) | KDM4EL3MBTL1ALDH1A1NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| CN-114502158-A | IRAK degradation agent and application thereof | 凯麦拉医疗公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3989966-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | KDM4E 240/4885L3MBTL1 398/4885ALDH1A1 4348/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | KDM4E 628/4885L3MBTL1 3031/4885ALDH1A1 3721/4885 |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885L3MBTL1 1394/4885ALDH1A1 2776/4885 |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK4, IRAK2, IRAK3 | KDM4E 87/4885L3MBTL1 154/4885ALDH1A1 3918/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885L3MBTL1 1394/4885ALDH1A1 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.